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Neuropathic pain is a challenging condition for which current therapies often remain
unsatisfactory. Chronic administration of β2 adrenergic agonists, including formoterol
currently used to treat asthma and chronic obstructive pulmonary disease, alleviates
mechanical allodynia in the sciatic nerve cuff model of neuropathic pain. The limited
clinical data currently available also suggest that formoterol would be a suitable
candidate for drug repurposing. The antiallodynic action of β2 adrenergic agonists is
known to require activation of the delta-opioid (DOP) receptor but better knowledge
of the molecular mechanisms involved is necessary. Using a mouse line in which
DOP receptors were selectively ablated in neurons expressing Nav1.8 sodium channels
(DOP cKO), we showed that these DOP peripheral receptors were necessary for
the antiallodynic action of the β2 adrenergic agonist formoterol in the cuff model.
Using a knock-in mouse line expressing a fluorescent version of the DOP receptor
fused with the enhanced green fluorescent protein (DOPeGFP), we established in a
previous study, that mechanical allodynia is associated with a smaller percentage of
DOPeGFP positive small peptidergic sensory neurons in dorsal root ganglia (DRG),
with a reduced density of DOPeGFP positive free nerve endings in the skin and with
increased DOPeGFP expression at the cell surface. Here, we showed that the density of
DOPeGFP positive free nerve endings in the skin is partially restored and no increase
in DOPeGFP translocation to the plasma membrane is observed in mice in which
mechanical pain is alleviated upon chronic oral administration of formoterol. This study,
Abbreviations: ANOVA, analysis of variance; CGRP, calcitonin gene-related peptide; cKO, conditional knockout;
DOP, delta-opioid; DRG, dorsal root ganglion; eGFP, enhanced green fluorescent protein; IENF, intraepidermal nerve
fiber; KS, Kolmogorov–Smirnov; KW, Kruskal–Wallis; PWT, paw withdrawal threshold; SNRI, serotonin noradrenaline
reuptake inhibitor.
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therefore, extends our previous results by confirming that changes in the mechanical
threshold are associated with changes in peripheral DOP profile. It also highlights the
common impact on DOP receptors between serotonin noradrenaline reuptake inhibitors
such as duloxetine and the β2 mimetic formoterol.
Keywords: mechanical allodynia, beta-mimetics, peripheral nerve injury, cuff model, delta opioid receptor, beta
adrenergic receptor
INTRODUCTION
Neuropathic pain arises from traumatic nerve injury or
from a disease that affects the somatosensory system and is
characterized by spontaneous pain, mechanical allodynia and/or
thermal hypersensitivity (von Hehn et al., 2012). First-line
treatments include antidepressants such as serotonin and
noradrenaline reuptake inhibitors (SNRIs), or anticonvulsants
such as gabapentinoids (Kremer et al., 2016a). In preclinical
studies, activation of the β2-adrenergic receptors has been
shown to be mandatory for the antiallodynic action of
antidepressants (Yalcin et al., 2009; Kremer et al., 2016a, 2018)
and chronic administration of several β2-adrenergic agonists
such as formoterol has been successfully used to alleviate
mechanical allodynia (Choucair-Jaafar et al., 2009, 2014; Yalcin
et al., 2010; Jourdain and Hatakeyama, 2019). Formoterol is
already routinely used in clinics to treat chronic obstructive
pulmonary disease (Vanfleteren et al., 2018). Also, inhalation
of β2-agonists during the perioperative period was associated
with a five-fold lower risk of developing post-thoracotomy
neuropathic pain whereas chronic antidepressants or chronic
gabapentanoids appeared ineffective (Salvat et al., 2015).
Drug repurposing could, therefore, be envisaged to treat
neuropathic pain.
Themechanisms underlying the relief of mechanical allodynia
are the topic of extensive research in various preclinical
models but remain unclear. Interestingly, delta-opioid (DOP)
receptors are essential for the antiallodynic effect of DOP
agonists (Nozaki et al., 2012; Vicario et al., 2016) but also
for the antiallodynic effect of chronic administration of both
antidepressants (Benbouzid et al., 2008b; Yalcin et al., 2010;
Ceredig et al., 2018; Kremer et al., 2018) and β2 mimetics
(Yalcin et al., 2010; Choucair-Jaafar et al., 2014). More
specifically, our previous work using the cuff model pointed
to peripheral DOP receptors expressed in Nav1.8 positive
neurons as mandatory for the antiallodynic action of DOP
agonists (Gaveriaux-Ruff et al., 2011; Nozaki et al., 2012)
as well as the SNRI duloxetine (Ceredig et al., 2018). Our
data also revealed that changes in the expression profile of
peripheral DOP receptors correlated with mechanical allodynia.
Indeed, we observed decreased DOP receptor expression in
unmyelinated calcitonin gene-related peptide (CGRP) positive
neurons and free nerve endings in the skin and increased
surface expression in the neurons still expressing the receptor
in neuropathic conditions but not in mice chronically treated
with duloxetine after cuff surgery (Ceredig et al., 2018). Here,
we sought to determine whether the same mechanisms are
triggered by chronic treatment with the β2 adrenergic agonist
formoterol by identifying changes in the expression of peripheral
DOP receptor using a mouse line in which peripheral DOP
receptors are selectively ablated in neurons expressing the
Nav1.8 sodium channel (DOP cKO; Gaveriaux-Ruff et al.,
2011) and a knock-in mouse line expressing DOP receptors
fused to the green fluorescent protein eGFP (DOPeGFP;
Scherrer et al., 2006). Our data indicate that peripheral DOP
receptors expressed in Nav1.8+ neurons were mandatory for
formoterol anti-allodynic activity. DOP surface expression was
lower in animals treated with chronic formoterol compared to
neuropathic conditions. However, DOP receptor expression was
only partially restored in nerve free endings in the skin and
remained similar to the neuropathic conditions in the dorsal
root ganglia (DRG) after chronic formoterol. Altogether, data
suggest that antidepressants and β2 mimetics effects engage
similar DOP-dependent mechanisms.
MATERIALS AND METHODS
Animals
DOPeGFP knock-in mice expressing the DOP receptor
infusion with the green fluorescent protein were generated
by homologous recombination. In these animals, the eGFP
cDNA preceded by a five amino acid linker (G-S-I-A-T)
was introduced into the exon 3 of the DOP receptor gene,
in the frame and 5’ from the stop codon (Scherrer et al.,
2006). The genetic background of DOPeGFP mice was
C57BL/6J:129SvPas (50%:50%). DOP-floxed (Oprd1fl/fl) mice
were interbred with Nav1.8-Cre mice to generate conditional
knockout (cKO) of DOP in primary nociceptive neurons
(Nav1.8-Cre × Oprd1fl/fl or DOPcKO) as previously reported
(Gaveriaux-Ruff et al., 2011). The genetic background of
conditional DOP knock-out mice and their floxed controls
was C57BL/6J:129SvPas (62.5%:37.5%). These mice were
bred at the ICS animal facility, Illkirch, France, and kindly
provided by Pr. Claire Gavériaux-Ruff. Adult male and female
mice aged 6–20 weeks, weighing 20–32 g for females and
20–38 g for males were used. Animals from independent
cohorts were distributed at best to provide groups of similar
size for each gender and treatment (n = 88 DOPeGFP
mice, n = 22 DOPcKO mice, n = 20 DOP-floxed mice).
Mice were group-housed 2–5 per cage, under standard
laboratory conditions (12 h dark/light cycle, lights on at
7 am) in temperature (21 ± 1◦C) and humidity (55 ± 10%)
controlled rooms with food and water ad libitum. All
experiments were approved by the ‘‘Comité d’Ethique
en Matière d’Expérimentation Animale de Strasbourg’’
[authorization number 201503041113547 (APAFIS#300).02] and
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conducted in agreement with the EU Directive 2010/63/EU for
animal experiments.
Neuropathic Pain Model
Neuropathic pain was induced by cuffing the main branch
of the right sciatic nerve as previously described (Benbouzid
et al., 2008c; Yalcin et al., 2014). Before surgeries, mice were
anesthetized with ketamine (Vibrac, Carros, France)/xylazine
(Rompun, Kiel, Germany; 100/10 mg/kg, i.p.). The common
branch of the right sciatic nerve was exposed, and a cuff
of PE-20 polyethylene tubing (Harvard Apparatus, Les Ulis,
France) of standardized length (2 mm) was unilaterally inserted
around it (Cuff group). Sham-operated animals underwent
the same surgical procedure without cuff implantation (Sham
group). Animals were placed on their left side in a clean
home cage immediately after surgery and kept under the
heat lamp until they awoke. Water and chow were placed
directly in the home cage. The surgical site was checked
daily during the next 3 days, and animals were monitored
for signs of unusual suffering or infection with endpoints
defined in agreement with the recommendations of the
ethical committee.
Assessment of Mechanical Allodynia
Mechanical allodynia was tested using von Frey filaments and
results were expressed in grams as described in Yalcin et al.
(2014). Briefly, calibrated von Frey filaments (Bioseb, Vitrolles,
France) were applied to the plantar surface of each hind paw
until they just bent, in a series of ascending forces up to
the mechanical threshold. Filaments were tested five times per
paw and the paw withdrawal threshold (PWT) was defined
as the lower of two consecutive filaments for which three
or more withdrawals out of the five trials were observed
(Yalcin et al., 2014).
Treatment Procedures
Treatment with the β2-adrenergic agonist formoterol began
4 weeks after the surgical procedure and lasted 4 weeks.
Formoterol (Cat. Nr BG0369, Biotrend AG, Switzerland) was
delivered by ad libitum access and as sole source of fluid
dissolved in drinking water at a dose of 0.5 µg/ml (equivalent
to 0.05 mg/kg/day) with 0.2% saccharin (Cat. Nr S1002,
Sigma Aldrich, St Louis, MO, USA). Experimental groups for
DOPeGFP mice included the Sham group (n = 36, 29 females
and seven males), Cuff group (n = 29, 16 females and
13 males), and Formoterol group corresponding to Cuff mice
treated with formoterol (n = 23, 14 females and nine males).
Experimental groups for DOP cKO mice included Sham
group (n = 6, two females and four males), Cuff group
(n = 5 males), and Formoterol group corresponding to
Cuff mice treated with formoterol (n = 11, seven females
and four males). Experimental groups for control littermates
Oprd1fl/fl (floxed mice) included Sham group (n = 7, five females
and two males), Cuff group (n = 5 males), and Formoterol
group corresponding to Cuff mice treated with formoterol
(n = 8, two females and six males). Sham and Cuff groups both
received control saccharin solution 0.2% in drinking water. Sham
and Cuff groups were identical to those published previously
in Ceredig et al. (2018).
Tissue Preparation
and Immunohistochemistry
Mice were anesthetized with ketamine (Vibrac, Carros,
France)/xylazine (Rompun, Kiel, Germany; 100/10 mg/kg,
i.p.) and perfused intracardially with 100 ml of ice-cold
(2–4◦C) 4% paraformaldehyde (PFA) in phosphate buffer
0.1 M pH 7.4 (PB). Ipsilateral (right) and contralateral (left)
L4 to L6 lumbar DRG were dissected out and post-fixed
for 90–120 mins at 4◦C in 4% PFA in PB, cryoprotected
at 4◦C in 30% sucrose in PB for 24 h, embedded in
OCT (Optimal Cutting Temperature medium, Thermo
Fisher Scientific, Waltham, MA, USA), frozen and kept
at −80◦C. DRG longitudinal sections (16 µm thick) were
cut with a cryostat (Microm Cryo-star HM560) and kept
floating in PB.
Immunohistochemistry was performed according to standard
protocols as previously described in Ceredig et al. (2018). Briefly,
DRG sections were incubated for 1 h at room temperature (RT)
in the blocking solution consisting of PB with 0.2% Tween
20 (PBT; Cat. Nr 85114, Thermo Fisher Scientific, Waltham,
MA, USA), 3% normal goat serum (Invitrogen, Paisley, UK)
and 3% donkey serum when needed (D9663 Sigma-Aldrich, St
Quentin Fallavier, France). The sections were then incubated
overnight at 4◦C in the blocking solution with the appropriate
primary antibodies: polyclonal rabbit anti-GFP (Cat. Nr A-
11122, Invitrogen, dilution 1:1,000), sheep polyclonal anti-CGRP
(Cat. Nr. AB 22560, Abcam, dilution 1:2,000). Three washes
were performed with PBT before sections incubated for 2 h
at RT in dim light with goat anti-rabbit IgG conjugated with
Alexa Fluor 488 (Cat. Nr A-11012, Molecular Probes, dilution
1:2,000) and donkey anti-sheep IgG conjugated with Alexa Fluor
594 (Cat. Nr A-11016, Molecular Probes, dilution 1:2,000).
Following three washes with PBT, the sections were mounted
with MOWIOL (Calbiochem, Darmstadt, Germany) and 4,6-
diamino-phenylindole (DAPI; Roche Diagnostic, Mannheim,
Germany; 0.5 µg/ml).
Plantar skin of both hind paws (footpad and glabrous skin,
1 cm long) were fixed at 4◦C in 4% PFA solution overnight,
cryoprotected overnight with 30% sucrose in PB, embedded in
OCT, frozen and kept at −80◦C. Longitudinal cross-sections
(50 µm thickness) were cut with a cryostat (MicromCryo-star
HM560) and kept floating in PB. Paw tissue samples were then
processed to visualize primary afferent terminals in the skin of
the hind paw as previously described in Ceredig et al. (2018).
Briefly, sections were treated with 0.3% H2O2, dehydrated with
successive baths in ethanol then rehydrated, washed 3 times with
PBS and incubated in blocking solution (PBS, 0.5% Triton X100
(PBST) with 3% normal goat serum or normal donkey serum)
for 30 min at RT. After overnight incubation at 4◦C in the
blocking solution, the sections were incubated with the primary
antibodies against anti-GFP (1:1,000) or anti-CGRP (1:2,000)
antibody. The sections were then washed three times with PBST,
respectively incubated for 2 h at RT with anti-rabbit or anti-goat
biotinylated secondary antibody (1:400) in PBST and washed
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again three times with PBST before staining with Vector SG (Sk-
4700, VectorLab). Samples were mounted with MOWIOL.
Image Acquisition and Analysis
Image acquisition and analysis were performed as previously
described in Ceredig et al. (2018). Briefly, images were acquired
with the Leica TCS SP5 confocal microscope using a 20× dry
objective (Numerical Aperture: 0.7), the 40× resolution was
achieved with a digital zoom factor. Confocal acquisitions in
the sequential mode (single excitation beams: 405, 488 and
568 nm) were used for marker co-localization to avoid potential
crosstalk between the different fluorescence emissions. Images
were acquired with the LCS (Leica) software using randomly
selected sections.
The ImageJr software cell counter (approximately 15
non-adjacent sections per condition and per animal) was used to
count on-screen neurons expressing a given fluorescent marker
manually and blindly. Threshold was applied to fluorescence
detection. Only neurons from L4-L6 DRGs with a visible nucleus
were considered. Cells expressing a given marker and eGFP
fluorescence were analyzed separately. During the analysis, we
recorded all cross-sectional areas of cell profiles for each marker.
No difference was observed in the distribution of the neuronal
populations between male and female mice and data were pooled
for subsequent analysis.
DOPeGFP subcellular distribution was expressed as a
ratio of membrane-associated vs. cytoplasmic fluorescence
densities determined as previously described (Erbs et al.,
2016). Acquisitions using 63× (NA: 1.4) oil objective were
performed to determine DOPeGFP subcellular distribution.
Briefly, quantification of internalization was performed using
the ImageJ software on 8-bit raw confocal images from
neurons randomly sampled. Nuclear fluorescence was used
to define the background level (no threshold was applied).
Cytosolic fluorescence intensity was subtracted from whole-cell
fluorescence intensity to obtain surface fluorescence intensity.
Fluorescence intensity values were divided per surface unit
(pixel) to obtain densities. Ratio of membrane-associated (Df
memb) vs. cytoplasmic (Df cyto) fluorescence densities was
calculated to normalize data across neurons examined. A value
of 1.0 results from equal densities of DOPeGFP at the cell surface
and in the cytoplasm.
Free nerve endings in the glabrous part of the skin were
visualized using a 20× dry objective (Nikon Eclipse 80i).
Counting on blinded samples was performedmanually on screen
using the Neurolucida software (V.10 MBF Bioscience) on at
least four randomly chosen sections per animal. Density was
obtained by dividing the number of afferents crossing the
dermal-epidermal junction excluding secondary branching, by
the total length of the section (Lauria et al., 2005).
Statistical Analysis
Behavioral analysis of von Frey testing was performed using
Statistica v12 (StatSoft, France) and Graph-Pad Prism v7
(GraphPad, San Diego, CA, USA). Changes in the PWT,
as a function of post-operative time (within factor) and
experimental treatment (between factor), were analyzed using
two-way ANOVA with repeated measures (two-way rANOVA)
analysis followed by Tukey HSD post hoc test. Baseline PWT
in males and females were compared using a two-sample
student’s t-test. Exact p-values below 0.0001 were not provided
for behavioral data (Graph-Pad Prism v7, GraphPad, San
Diego, CA, USA). For cross-sectional area measurements, data
were pooled per treatment group for each marker (CGRP or
eGFP). In all groups, cross-sectional areas were found not
normally distributed (p-value always < 10−8, Shapiro–Wilk
test) using R (R Core Team, 2017). Sums of Gaussian
functions were therefore adapted to the relative cumulative
distribution curve of cell size, using non-linear least-square
curve fitting (with nls2, nlstools and pracma R packages).
Data were expressed as cumulative distributions to allow direct
determination of the mean and standard error by adjusting the
function of repartition on the experimental points. We compared
the cumulative distributions for the various groups using
the non-parametric Kolmogorov–Smirnov test (R). Treatment
impact in DOPeGFP+ bins was analyzed using multiple t-tests.
Statistical analysis of DOPeGFP subcellular distribution and
skin fiber was performed with one-way ANOVA followed by
Tuckey HSD post hoc test (Graph-Pad Prism v7, GraphPad, San
Diego, CA, USA). Co-localization of DOPeGFP with neuronal
markers in small size neurons (<300 µm2) was analyzed using
the non-parametric Kruskal–Wallis test followed by Dunn’s
post hoc test.
RESULTS
Chronic Formoterol Requires DOP
Receptors Expressed in Nav1.8+ Neurons
for Anti-allodynic Action
We previously established that mechanical allodynia is induced
by cuff-implantation, developed directly after surgery and was
maintained until up to 12–14 weeks (Yalcin et al., 2011). Also,
DOP receptors expressed in Nav1.8+ neurons were shown to
be mandatory for the anti-allodynic action of the antidepressant
duloxetine in the cuff model (Ceredig et al., 2018). Since
DOP receptors are also required for the anti-allodynic effect
of a chronic treatment with the β2 agonist clenbuterol (Yalcin
et al., 2010), we investigated whether the specific deletion of
DOP receptors in primary afferents (peripheral DRG neurons)
expressing Nav1.8 voltage-gated sodium channels (DOPcKO;
Gaveriaux-Ruff et al., 2011) was also abolishing the antiallodynic
action of a β2-adrenergic agonist.
Von Frey testing revealed that sciatic nerve cuffing resulted
in unilateral mechanical allodynia in DOPcKO and control
floxed (DOPfl/fl) animals (Figures 1A,B) as previously reported
(Ceredig et al., 2018). Cuff DOPcKO mice did not recover after
formoterol treatment in drinking water (50 µg/ml; two-way
rANOVA, interaction treatment × time F(12,114) = 11.31,
p < 0.0001, effect of time F(6,114) = 33.37, p < 0.0001,
effect of treatment F(2,19) = 112.8, p < 0.0001, Tukey HSD
post hoc test: formoterol treatment from day 28 to 39 vs.
Sham, p < 0.0001 at each time-point; Figure 1A), whereas
control DOPfl/fl Cuff animals treated with formoterol returned
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FIGURE 1 | Expression of delta-opioid (DOP) receptors in Nav1.8+ neurons was mandatory for oral formoterol anti-allodynic action. The right (ipsilateral) hind paw
mechanical threshold was tested using von Frey calibrated filaments. Following cuff implantation surgery, animals had lowered paw withdrawal thresholds (PWT),
displaying sustained mechanical allodynia. Formoterol (0.5 µg/ml) or saccharin 0.2% control per os treatments started 4 weeks after nerve injury and were
maintained for 3 weeks. (A) Mechanical threshold of the right (ipsilateral) hind paw in DOP cKO mice. Data from three separate experiments (each including the three
conditions) were pooled and are expressed as means ± SEM. Sham (n = 6), Cuff (n = 5), Cuff treated with formoterol (n = 11). Two-way rANOVA and Tukey HSD
post hoc test: ****p < 0.001 formoterol treatment vs. baseline. (B) Mechanical threshold of the right (ipsilateral) hind paw in control floxed mice. Data from three
separate experiments (each including the three conditions) were pooled and are expressed as means ± SEM. Sham (n = 7), Cuff (n = 5), Cuff treated with formoterol
(n = 8). Two-way rANOVA and Tukey HSD post hoc test: ****p < 0.0001, **p < 0.01 formoterol treatment day 39 vs. baseline: p = 0.3284.
FIGURE 2 | Chronic formoterol treatment per os relieved mechanical allodynia in DOPeGFP knock-in mice. The right (ipsilateral) hind paw mechanical threshold was
tested using von Frey calibrated filaments in male and female DOPeGFP KI mice. Males (A) and females (B) had lowered PWT following cuff implantation surgery,
i.e., sustained mechanical allodynia. Four weeks after nerve injury, formoterol (0.5 µg/ml) or saccharin 0.2% control per os treatments started and were maintained
for 4 weeks. Data from three separate experiments (each including the three conditions) were pooled and are expressed as means ± SEM. Sham (n = 7 males and
29 females), Cuff (n = 13 males and 16 females), Cuff treated with formoterol (n = 9 males and 14 females). Two-way rANOVA and Tukey HSD post hoc test:
*p < 0.05, ***p < 0.001, ****p < 0.0001 vs. Sham. #### p < 0.001 vs. Cuff.
to baseline values at day 39, after 11 days of formoterol
administration (two-way rANOVA interaction treatment× time
F(12,119) = 8.386, p < 0.0001, effect of time F(6,119) = 18.56,
p < 0.0001, effect of treatment F(2,119) = 84.47, p < 0.0001,
Tukey HSD post hoc test: formoterol treatment vs. Sham:
p < 0.0001 from day 28 to 32, p < 0.01 from day
33 to day 38, p = 0.33 on day 39; Figure 1B). Our result
therefore established that DOP receptors in Nav1.8 positive
neurons were mandatory to alleviate mechanical allodynia
upon chronic treatment with the β2 mimetic formoterol.
We thus assessed in more detail the impact of chronic
formoterol treatment on neuronal populations expressing
the DOP receptor using the DOPeGFP fluorescent knock-in
mouse line.
Chronic Formoterol Alleviates
Cuff-Induced Mechanical Allodynia in
DOPeGFP Mice
We first verified that oral administration of the β2 adrenergic
agonist-induced the expected anti-allodynic effect in the
DOPeGFP knock-in mouse line. As previously reported (Ceredig
et al., 2018), males had significantly higher baseline mechanical
thresholds compared to females (5.4 ± 0.4 g for males vs.
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FIGURE 3 | DOPeGFP distribution in Sham, Cuff and Formoterol-treated animals. (A) Representative confocal image of fluorescent DOPeGFP expressing neurons
in lumbar dorsal root ganglia (DRG) of sham animals. Scale bar 10 µm. (B) Distribution of DOPeGFP+ neuronal populations in Sham (3,080 neurons, n = 7 animals;
light gray), Cuff (3,123 neurons, n = 6 animals; black) and Formoterol (1,917 neurons, n = 5 animals; dark gray) groups. (C) Categorical data plot of the size
distribution for DOPeGFP positive neuron cross-sectional areas in Sham (white bars), Cuff (black bars) and Formoterol (checked bars) groups. Multiple t-tests:
*p = 0.03 Cuff vs. Sham, *p = 0.01 Formoterol vs. Sham.
3.5 ± 0.2 g for females, student’s t-test for baseline values:
t = 7.18 p < 0.0001) and cuff implantation induced ipsilateral
mechanical allodynia which lasted for at least 8 weeks (time of
perfusion) in either sex (two-way rANOVA; males interaction
treatment × time F(16,208) = 15.15, p < 0.0001; effect of
treatment, F(2,26) = 318.5, p < 0.0001 from day 21 to 57 Cuff
vs. Sham; females interaction treatment × time F(16,448) = 11.02,
p< 0.0001, effect of treatment F(2,56) = 236, p< 0.0001 from day
21 to 57 Cuff vs. Sham; Figures 2A,B). We did not detect any
change in the nociceptive threshold after sham surgery or in the
contralateral hind paw of Cuff animals (data not shown).
Formoterol treatment in drinking water (50 µg/ml)
relieved mechanical allodynia at day 51 (following 23 days
administration) in DOPeGFP males although not fully (two-
way rANOVA Tukey HSD post hoc test: day 51 vs. Sham:
p(Males) = 0.0009 and day 57 vs. Sham: p(Males) < 0.0001,
day 51 and day 57 vs. Cuff: p(Males) < 0.0001; Figure 2A).
In DOPeGFP females, formoterol treatment-induced almost
complete relief at day 51 (two-way rANOVA Tukey HSD post
hoc test: day 51 vs. Sham: p(Females) = 0.0382) and values were
similar to sham mice at day 57 (two-way rANOVA Tukey HSD
post hoc test: day 57 vs. Sham: p(Females) = 0.3547, day 51 and day
57 vs. Cuff: p(Females) < 0.0001; Figure 2B). This time course was
similar to what we previously observed, in the same model, in
male C57BL6/J mice repeatedly injected i.p. twice daily (Yalcin
et al., 2010).
DOPeGFP Expression in
Formoterol-Treated Mice
We then examined changes in the distribution of DOPeGFP+
neurons in the DRG (Figure 3A). As previously established
(Ceredig et al., 2018), the cumulative distribution of DOPeGFP+
cells in the Cuff experimental groups was shifted towards larger
cell size values compared to the Sham group (Figure 3B). The loss
of DOPeGFP+ neurons with small cross-sectional areas (Multiple
t-tests: Cuff vs. Sham: p = 0.03 for the 100–200 µm2 category)
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FIGURE 4 | Impact of formoterol treatment on DOPeGFP colocalization with CGRP+ populations. (A) Representative fluorescence micrographs showing DOPeGFP
co-localization with the neuronal marker calcitonin gene-related peptide (CGRP; red) as indicated by arrows in the overlay figure. Nuclei are stained with DAPI (blue).
Scale bar 10 µm. (B) Distribution of CGRP+ neuronal populations in Sham (3,351 neurons, n = 7 animals; light gray), Cuff (1,331 neurons, n = 6 animals; black), and
Formoterol (1,311 neurons, n = 5 animals; dark gray). (C) Distribution of neuronal populations co-expressing DOPeGFP and CGRP in Sham (803 neurons,
n = 7 animals; light gray), Cuff (438 neurons, n = 6 animals; black) and Formoterol (294 neurons, n = 5 animals; dark gray) groups. (D) Percentage of cells
co-expressing DOPeGFP and CGRP in neurons with areas <300 µm2 in Sham (n = 6; •), Cuff (n = 6; ) or Formoterol (n = 5; N) animals. Values expressed as
mean ± SEM. Kruskal–Wallis test and Dunn’s post-test: *p < 0.05, ***p < 0.001 vs. Sham.
indicated a loss of DOPeGFP expression in small and/or medium
neurons following 8 weeks of neuropathy (Figure 3C).
In Cuff mice chronically treated with formoterol, the
distribution of the DOPeGFP+ neuronal populations remained
very similar to the Cuff condition and was significantly different
from the Sham group (KS test: D = 0.14212, p < 2.2 10−16;
Figure 3B). Indeed, the percentage of small size neurons
remained lower compared to the Sham condition (Multiple
t-tests: Formoterol vs. Sham: p = 0.0137 for the 100–200 µm2
category; Figure 3C).
Since DOPeGFP expression was decreased in unmyelinated
peptidergic populations in Cuff mice (Figure 3) and (Ceredig
et al., 2018), we assessed the consequence of chronic formoterol
treatment on the global CGRP+ population and on the
proportion of the CGRP+ population also expressing DOPeGFP
(Figure 4). The cumulative distribution corresponding to
CGRP+ neurons showed that the shift towards larger cell size
values in the Cuff group is no longer present for the smallest
cross-sectional areas after treatment with formoterol although
the overall distribution remained significantly distinct from the
Sham group (KS test: D = 0.090945, p = 3.398 10−7; Figure 4B).
However, the cumulative distribution of the CGRP+DOPeGFP+
neurons remained similar to the cuff condition and was
significantly different from the Sham condition (KS test:
D = 0.15672, p < 2.2 10−16; Figure 4C) with the proportion of
small size neurons (<300 µm2; 6.7± 0.8%) remaining similar to
the Cuff condition (4.3± 0.5%) and lower compared to the Sham
condition (16.5 ± 1.3%; KW test: p < 0.0001, Dunn’s post hoc
test Sham vs. Cuff p = 0.0007, Sham vs. Formoterol p = 0.0352,
Cuff vs. Formoterol p > 0.9999; Figure 4D). Therefore, chronic
treatment with formoterol did not appear to restore the loss of
DOPeGFP+ neurons induced by the neuropathic condition in
small peptidergic neurons.
DOPeGFP Expression at the Plasma
Membrane in Formoterol-Treated Mice
Enhanced DOP expression at the plasma membrane was
previously described in neuropathic conditions (Gendron et al.,
2015). This observation was confirmed in the cuff model
by showing that the ratio of fluorescence associated with
the cell surface was significantly increased compared to the
fluorescence associated with the intracellular compartments
in the DOPeGFP+ neurons (Figure 5) as also previously
reported (Ceredig et al., 2018). Formoterol treatment decreased
membrane-associated fluorescence to values which were even
lower than those of neurons in the Sham condition (Sham
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FIGURE 5 | DOPeGFP expression at the cell surface in Formoterol-treated
mice. (A) Representative fluorescence micrographs of DOPeGFP-positive
neuron in Sham, Cuff and cuff animals treated with formoterol. Scale bar
10 µm. (B) DOPeGFP subcellular distribution was increased in neuropathic
conditions and reduced after formoterol treatment compared to Sham. Data
are expressed as means ± SEM (Sham: n = 32 cells from four animals, Cuff:
n = 30 cells from three animals, Formoterol: n = 30 cells from three animals).
One-way ANOVA and Tukey HSD post hoc test: **p < 0.01, ***p < 0.001 vs.
Sham and #### p < 0.0001 vs. Cuff, p > 0.5 Formoterol vs. Cuff.
1.16 ± 0.03, Cuff: 1.35 ± 0.04, formoterol 0.94 ± 0.05, one-way
ANOVA F(2,89 = 28.8 p < 0.0001 Tukey HSD post hoc test Cuff
vs. Sham p = 0.002, Cuff vs. Formoterol p < 0.0001, Sham vs.
Formoterol p = 0.0002; Figure 5B). This indicates that treatment
with formoterol suppressed the increase in DOP receptor surface
expression observed in neuropathic mice.
CGRP and DOPeGFP Expression in the
Skin of Formoterol Treated Mice
A decrease in CGRP+ intra-epidermal nerve fiber (IENF) fiber
length and density, as well as decrease in DOPeGFP+ IENF
density, was reported 8 weeks post cuff surgery (Nascimento
et al., 2015; Ceredig et al., 2018). We thus assessed whether
treatment with formoterol impacted CGRP+ and DOPeGFP+
IENFs (Figure 6). The density of CGRP+ IENFs in the glabrous
skin of the hind paw of cuffed mice treated with formoterol
remained at a level comparable to the Cuff group (one-way
ANOVA F(2,8) = 49.15, p < 0.0001; Tukey HSD post hoc test
Sham vs. Cuff p< 0.0001, Sham vs. Formoterol p< 0.0001, Cuff
vs. Formoterol p = 0.771; Figure 6B). The density of DOPeGFP+
IENFs was higher in formoterol treated animals compared to
the Cuff group but remained significantly lower compared to
the Sham condition [one-way ANOVA F(2,9) = 371, p < 0.0001;
Tukey HSD post hoc test Sham vs. Cuff p < 0.0001, Sham
vs. Formoterol p < 0.0001, Cuff vs. Formoterol p = 0.0008
(Figure 6C)]. As a whole, chronic formoterol treatment did
not restore CGRP+ expression and induced partial recovery of
DOPeGFP expression in the IENFs.
DISCUSSION
We first showed that oral administration of the β2 adrenergic
agonist formoterol was as effective as its intraperitoneal injection
(Yalcin et al., 2010) to alleviate mechanical allodynia in the
cuff model of neuropathy. We then identified peripheral
DOP receptors as mandatory for the antiallodynic effect and
determined the impact of chronic formoterol on the expression
of DOP receptors in the lumbar DRGs and skin IENFs.
Several studies pointed to the role of DOP receptors, and
more specifically peripheral DOP receptors present in Nav1.8+
neurons, to counteract mechanical allodynia in neuropathic
conditions induced by sciatic nerve ligation (Nadal et al., 2006;
Gaveriaux-Ruff et al., 2011; Nozaki et al., 2012). Previous work
by the group established that the antiallodynic action of chronic
tricyclic antidepressant and SNRI treatments require DOP and
β2 adrenergic receptors (Yalcin et al., 2010; Choucair-Jaafar
et al., 2014; Kremer et al., 2018). Systemic administration of
the DOP antagonist naltrindole also blocked the antiallodynic
action of chronic administration of β2 adrenergic agonists
(Yalcin et al., 2010; Choucair-Jaafar et al., 2014). In the case
of the SNRI duloxetine, peripheral DOP receptors expressed
in Nav1.8+ neurons were mandatory for the antiallodynic
effect as no recovery was observed in the DOP cKO mouse
line in which peripheral DOP receptors were selectively
ablated in neurons expressing the Nav1.8 sodium channel
(Ceredig et al., 2018). Here, we showed that peripheral
DOP receptors expressed in Nav1.8+ neurons were also
mandatory for the β2-adrenergic agonist formoterol to alleviate
mechanical allodynia. Our results, therefore, establish that
peripheral DOP receptors, likely located on C nociceptors,
are necessary for the effective antiallodynic effect of the two
chronic treatments. They also suggest that DOP receptor
expression is modulated by the noradrenergic component
of SNRIs.
In our previous work, we have characterized changes in DRG
neuronal populations in the neuropathic condition resulting
from sciatic nerve cuffing (Ceredig et al., 2018). Our main
findings highlighted a decrease in the proportion of small
size peptidergic neurons (≤300 µm2) and IENFs expressing
DOPeGFP 8 weeks after cuff surgery as well as increased
DOPeGFP expression at the plasma membrane (Ceredig
et al., 2018), suggesting that these changes may contribute
to control mechanical nociception. Here, we showed that
chronic formoterol administration promoted partial recovery
of DOPeGFP expression in free nerve endings in the skin but
not in small CGRP+ neurons in the DRGs. This contrasts with
the higher DOPeGFP expression found in small unmyelinated
peptidergic neurons (≤300 µm2) following chronic duloxetine
administration. The reason for this difference is unknown
but it could correspond to the use of a suboptimal dose
of formoterol as also suggested by the dose-response curve
performed using intraperitoneal injections (Yalcin et al.,
2010). It is indeed unlikely to depend on the serotoninergic
component of the SNRI action since selective serotonin
reuptake inhibitors did not alleviate mechanical allodynia
(Benbouzid et al., 2008a). Our results, however, confirmed that
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FIGURE 6 | Density of CGRP+ and DOPeGFP+ free nerve endings in the skin. Representative micrograph of (A) CGRP or DOPeGFP intra-epidermal nerve fiber
(IENF) labeling in the skin of Sham, Cuff and cuff animals treated with formoterol (black arrows). Scale bar 10 µm. (B) The density of CGRP+ free nerve endings in the
glabrous skin of the right hind paw was decreased in Cuff animals and Cuff animals treated with formoterol. Data are expressed as means ± SEM, n = 4 mice for
Sham and Cuff and n = 3 for Formoterol. One-way ANOVA and Tukey HSD post hoc test: ****p < 0.0001 vs. Sham. (C) The density of DOPeGFP+ free nerve endings
in the glabrous skin of the right hind paw was decreased in Cuff animals and only partially restored in Cuff animals treated with formoterol compared to Sham. Data
are expressed as means ± SEM, n = 4 mice per condition. One-way ANOVA and Tukey HSD post hoc test: ****p < 0.0001 vs. Sham, ### p < 0.001 vs. Cuff.
DOP expression in the nerve terminals, likely unmyelinated
peripheral axons of C mechanonociceptors (Brederson and
Honda, 2015) appeared a primary determinant of mechanical
sensitivity and might constitute a valuable marker of the
neuropathic state.
Chronic pain was shown to increase DOP receptor
translocation to the plasma membrane in the DRGs (reviewed
in Gendron et al., 2015) and our data showed a similar increase
in DOPeGFP surface expression in the cuff model. Chronic
formoterol was associated with low DOP receptor expression
at the plasma membrane that was even below values observed
in the sham condition. The low DOPeGFP expression at the
surface was also observed in mice chronically treated with
duloxetine (Ceredig et al., 2018) and, therefore, seems a common
mechanism bywhich the two antiallodynic treatments counteract
mechanical hypersensitivity. The underlying mechanisms,
however, remain elusive. DOP and β2 adrenergic receptors have
been proposed to form heteromers based on studies performed in
co-transfected cells (Jordan et al., 2001). However, β2 adrenergic
receptors are expressed in satellite cells in the DRGs (Bohren
et al., 2013) whereas DOP dependent analgesia is mediated at the
neuronal level (Gaveriaux-Ruff et al., 2011; Ceredig et al., 2018;
this work) and is independent of microglial activation (Mika
et al., 2014) which precludes direct molecular interactions. The
delayed antiallodynic action of both formoterol and duloxetine
suggests that it requires cellular adaptations to take place. Lesion
of peripheral noradrenergic fibers with guanethidine, a toxin that
does not cross the blood brain barrier abolished the antiallodynic
action of duloxetine (Kremer et al., 2018) supporting common
involvement of peripheral β2 adrenergic receptors. Formoterol
(Bohren et al., 2013) as well as antidepressants (Kremer et al.,
2018) counteracted the increase in TNFα associated with
neuropathic pain and downregulated the activity of the glial
NFκB-TNFα pathway, a key regulator of proinflammatory
cytokine production (Leung and Cahill, 2010). However, this
anti-neuroinflammatory action is also shared by gabapentinoids
that do not need opioid receptors for their antiallodynic action
(Kremer et al., 2016b). This rather supports a view in which
the anti-neuroinflammatory effect and the modulation of DOP
expression and activity are not directly related.
There are few clues as to which DOP-dependent mechanisms
mediate the anti-allodynic action following formoterol or SNRI
chronic treatment. Current data point to an indirect effect
through increased endogenous opioid peptide release by the
native and adaptative immune systems, which can activate
neuronal opioid receptors to alleviate mechanical allodynia
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(Binder et al., 2004; Celik et al., 2016). Indeed, noradrenergic
sprouting consequent to nerve injury would activate the β2-
adrenoceptors expressed by immune cells and promote the
release of enkephalin, dynorphin and β-endorphin by these cells
(Binder et al., 2004; Celik et al., 2016; Pannell et al., 2016).
Similarly, enkephalins are also present in the skin (Slominski
et al., 2011). Moreover, sympathetic fiber sprouting is known
to take place in the skin in the cuff model (Nascimento et al.,
2015) and is located close to cells expressing β2 adrenergic
receptors and β-endorphin in inflamed paw tissue providing
a way to activate not only MOP but also DOP receptors
(Binder et al., 2004). Activation of DOP receptors could, in
turn, induce pain relief by reducing Nav1.8 channel activity via
inhibition of p38 mitogen-activated protein kinase as described
for Nav1.7 channels in a rat model of diabetic neuropathy
(Chattopadhyay et al., 2008).
In summary, our work established that DOP receptors
expressed in Nav1.8+ neurons were mandatory for the
anti-allodynic action of chronic treatment with the β2 adrenergic
agonist formoterol. It also revealed that chronic formoterol
partially reversed the loss of peripheral DOP receptors in the
skin and counteracted enhanced DOP expression at the plasma
membrane. Our study thus adds to current literature pointing to
potential interest in repositioning β2 adrenergic agonists for the
treatment of neuropathic pain.
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